Research & Development: Page 64
-
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies By Carolyn Gretton New Alliance Promotes Trust in Online Physician Research Trend: Market research organizations, which base many critical decisions on insights from online physician panels, are taking collective action to ensure the integ...
By Carolyn Gretton • Jan. 26, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
INDUSTRY at Large Milestones… Spectrum Celebrates 15 Years Spectrum, a health and science communications agency, is celebrating its 15th anniversary. The independent agency, which was founded by John Seng in 1996, is committed to achieving the goals of clients who are involved with issues, pro...
By Taren Grom • Jan. 26, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Six Social Shifts: Trends Affecting Pharma Now
Like all things digital, the social media environment is moving so fast that even news from just three months ago seems old. The regulatory environment of pharma exacerbates the challenge to stay ahead of this social world. The pharma industry was anything but an early adopter in the social space...
By Whitney Poma • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Global: R&D Outsourcing
Robin Robinson Outsourcing has always been about cutting costs and creating efficiencies, and today’s pressures have made the R&D process more global than ever. Myriad pressures have the industry looking toward global R&D outsourcing as a life raft in a sea of change. A U.K. report by Del...
By Robin Robinson • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
The Littlest Patients
Denise Myshko Incentives and mandates have spurred drugmakers to test many products in children and to enhance the pediatric information provided on drug labels. But experts say there is still a long way to go to address this specialty population. Over the past 15 years, biopharmaceutical co...
By Denise Myshko • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Pharma 3.0 Next Steps
Robin Robinson Pharma Expands Disease Categories of 3.0 Efforts Between 2006 and 2009, 24% of Pharma 3.0 initiatives focused first on diabetes and metabolics. In 2010, oncology moved to the top with 15% of the year’s initiatives, and diabetes and metabolics tied for second with immunoscience/...
By PharmaVoice Team • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies By Carolyn Gretton Parexel Adds Commercialization to Repertoire Trend: A growing number of clinical development service providers are using their rich store of data and experience gleaned from clinical trial management to expand into commer...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton Pharma Turning to Health Outcomes Liaison Teams Trend: Trailblazing pharma companies are assembling elite health outcomes liaison (HOL) teams focused on market access priorities and supporting these groups ...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Online Investigator Training in Clinical Trials: A Roadmap For Success
A Roadmap for Success Successfully implementing online investigator training for clinical research sites requires technology and processes developed specifically for this purpose. As readers of this article are aware, research sites operate in a highly regulated and scrutinized environment. Sites...
By Suzanne Collins • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
The Increasing Role of the Patient in Phase IV Studies and Registries
Even though Phase IV studies and patient registries have been increasingly required by regulatory agencies for several years now and a wide range of technologies exist to design and manage them in an efficient manner, life-science organizations are still struggling to effectively implement large ...
By G. Chassaigne • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Showcase Feature: Building a Better E-Machine
Carolyn Gretton Technological innovation remains essential to ensuring companies’ success in the data-driven Pharma 3.0 environment. According to Ernst & Young’s Progressions 2011 report, the next-generation pharma ecosystem continues to gain complexity, with initiatives expanding across a br...
By Carolyn Gretton • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Global: A Shrinking World
Taren Grom Global reach, emerging markets, and cross-divisional expertise are playing an increasing role in all aspects of the life sciences, from R&D and clinical trials to sales and marketing. According to the IMS Institute for Healthcare Informatics, pharmerging markets will approach U....
By Taren Grom • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: The Drug Device Conundrum
Combining molecules with devices continues to be an evolving trend, but a lot of uncertainty exists around these combination products. There has been a movement toward convergence of technologies. More and more, drugs are being delivered or used in combination with a device with the intent to red...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: Global Regulatory Oversight
Growing regulatory requirements, continued standardization of submission and data requirements, and a continued focus on safety are just a few of the issues facing pharmaceutical companies. “With the FDA’s recent acceptance into PIC/S, an international agreement between countries’ regulatory ag...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: Strategic Outsourcing
CROs and pharmaceutical companies continue to finetune their strategic partnerships to gain a competitive edge. “”Companies are looking at outsourcing models that allow for sharper research focus, enhanced quality, improved efficiency, and offer a lower and more flexible cost base. " Alan Morgan...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
The C-Suite: Corporate Strategies
New Ways Forward Experts agree the time has come to re-evaluate the overall working culture of the life-sciences industry, and they say innovation, new payer models, new stakeholders, and new outcomes are key considerations for future success. “Pharma will need to generate data that are timely, r...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
C-Suite: Executive Insights
CEOs, presidents, and executive management team members from across the industry — pharmaceutical, biotechnology, and service companies — discuss the most crucial factors driving change in the industry, as well as their strategies for meeting the challenges of business in the coming years. Jed Be...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
The Year of the Extreme Makeover
Every sector in the industry is in a state of flux. In this special issue of PharmaVOICE, more than 160 thought leaders throughout the life-sciences industry discuss the changing market dynamics. According to PricewaterhouseCooper’s 14th Annual Global CEO Survey, which looks at the concerns expre...
By Denise Myshko and Robin Robinsons • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Percival BARRETTO-KO Astellas Realigns Executive Team Astellas US, the U.S. affiliate of Tokyo-based Astellas Pharma, has named Percival Barretto-Ko senior VP, corporate strategy and government affairs. Mr. Barretto-Ko was previously executive director, corporate strategy and ...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Healthcare Reform Viewed as Mixed Blessing Trend: Consumers believe the success of healthcare reform is dependent on achieving cost reduction and quality improvement — two things that traditionally stand in opposition to each...
By Carolyn Gretton • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
On the Calendar
Industry Events and Conferences, including SPECIAL DISCOUNTS Coming ATTRACTIONS Attendees interested in maximizing their clinical trial performance by bridging the gap between identifying and implementing metrics, learning about best practices on processing data and on-site performance to improve...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Connecting with Professional and Patient Targets: Going Back to the Future with Live Telephone Interviewing
More than a decade ago, the Internet took the market research world by storm. Online studies offer a fast, simple, cost-effective way to reach target audiences. A wide range of factors, however, often makes healthcare projects difficult to complete using online alone: Gatekeepers — such as office...
By Chris De Angelis • Sept. 27, 2011 -
PharmaVoice Team/PharmaVoice
Hello South Africa
A Diverse and Sophisticated Market With a diverse population, a thriving research environment, strong infrastructure along with geographic reach into the rest of Africa, South Africa has many advantages for the global pharma industry. With its population of more than 50 million people from divers...
By Kim Ribbink • Sept. 27, 2011 -
PharmaVoice Team/PharmaVoice
New Science Means New Ways to Target Disease
Epigenetics — the study of changes in gene expression — is rapidly emerging as a field that presents tremendous opportunity for drug discovery. We are on the edge of a new biology. It turns out that our genes are just part of the story about what makes us who we are. Much has been learned over ...
By Denise Myshko • Sept. 27, 2011 -
PharmaVoice Team/PharmaVoice
30 Years of AIDS Research
Antiretroviral agents have revolutionized treatment for HIV/AIDS. But there is still a tremendous need for prevention and less-costly therapies. Much progress has been made over the last 30 years in the HIV/AIDS arena. HIV infection is no longer considered a death sentence, thanks to antitretrov...
By Denise Myshko • Sept. 27, 2011
Previous
